Selected scientific publications
• Virus-like particle display of HER2 induces potent anti-cancer responses
OncoImmunology, Volume 7, Issue 30, 2018.
Arianna Palladini, Susan Thrane, Christoph M. Janitzek, Jessica Pihl, Stine B. Clemmensen, Willem Adriaan de Jongh, Thomas M. Clausen, Giordano Nicoletti, Lorena Landuzzi, Manuel L. Penichet, Tania Balboni, Marianna L. Ianzano, Veronica Giusti, Thor G. Theander, Morten A. Nielsen, Ali Salanti, Pier-Luigi Lollini, Patrizia Nanni & Adam F. Sander
• Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
In the present study targeting of human cancer cells with a glycosaminoglycan binding malaria protein (VAR2CSA) was investigated. The present work utilises Attana QCM technology to perform binding studies using both cell based and biochemical approaches.
Cancer Cell, Volume 28, Issue 4, p. 500–514, 2015.
Ali Salanti, Thomas M. Clausen, Mette Ø. Agerbæk, Nader Al Nakouzi, Madeleine Dahlbäck, Htoo Z. Oo, Sherry Lee, Tobias Gustavsson, Jamie R. Rich, Bradley J. Hedberg, Yang Mao, Line Barington, Marina A. Pereira, Janine LoBello, Makoto Endo, Ladan Fazli, Jo Soden, Chris K. Wang, Adam F. Sander, Robert Dagil, Susan Thrane, Peter J. Holst, Le Meng, Francesco Favero, Glen J. Weiss, Morten A. Nielsen, Jim Freeth, Torsten O. Nielsen, Joseph Zaia, Nhan L. Tran, Jeff Trent, John S. Babcook, Thor G. Theander, Poul H. Sorensen and Mads Daugaard
• Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting
The paper describes use of Attana QCM label free methodology to study molecular binding kinetics in situ on FFPE tissues. FFPE tissue sections of human placenta tissues and prostate cancer were immobilised on COP-1 surfaces using ploy-L-lysine solution. Interaction between vAR2 protein and its receptor has been analysed using Attana Cell 200 system. Affinity value in the nanomolor range was detected for the interaction between rVAR2 and its receptor and no detectable binding was observed with the haelthy tissues.
Sensing and Bio-Sensing Research, Volume 9, p. 23-30, 2016.
Thomas Mandel Clausen, Marina Ayres Pereira, Htoo Zarni Oo, Mafalda Resende, Tobias Gustavson, Yang Mao, Nobuo Sugiura, Janet Liew, Ladan Fazli, Thor G Theander, Mads Daugaard and Ali Salanti
• Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors
This study explores the effect of cell surface glycans on cancer therapy.
Scientific Reports 7, Article: 43006, 2017.
Diluka Peiris, Alexander F. Spector, Hannah Lomax-Browne, Tayebeh Azimi, Bala Ramesh, Marilena Loizidou, Hazel Welch and Miriam V. Dwek
• Combined Bacteria Microarray and Quartz Crystal Microbalance Approach for Exploring Glycosignatures of Nontypeable Haemophilus influenzae and Recognition by Host Lectins
The paper describes the use of the Attana Cell 200 instrument to characterize the glycosignature of bacteria (haemophilus influeanze). The bacteria have been immobilized using a ConA-LNB surface. Different lectins injected and the binding kinetic analyze. Comparison of the frequency shift obtained using different strains confirm the result obtained in micro-array.
Analytic Chemistry, Volume 88, Issue 11, p. 5950–5957, 2016.
Ioanna Kalograiaki, Begoñ a Euba,Davide Proverbio, María A. Campanero-Rhodes, Teodor Aastrup, Junkal Garmendia and Dolores Solís
• Facile fabrication of glycopolymer-based iron oxide nanoparticles and their applications in the carbohydrate–lectin interaction and targeted cell imaging.
A method for facile fabrication of carbohydrate-functionalized iron oxide NPs pre-coated with a glycopolymer was developed. The authors studied the binding affinities of these mannose and gluocose-functionalized NPS towards lectins immobilized on QCM chips (ConA, PNA or galectin-9) or on the surface of cells (colon cancer KM12 cells or Jurkat cells).
Polymer Chemistry, Issue 7, p. 1337-1344, 2016.
Chen Shao, Xueming Li, Zhichao Pei, Dongdong Liu, Lin Wang, Hai Dong and Yuxin Pei.
• Optimization of 3D Surfaces of Dextran with Different Molecule Weights for Real-Time Detection of Biomolecular Interactions by a QCM Biosensor
Participants - University Of Stuttgart, Biogelx Ltd, Attana AB.
Eurostars program for innovative SMEs co-finance the joint development project. The project is based on Attana's cell-based 3rd generation biosensors, Biogelx's 3D hydrogel matrix for cell growth and Prof. Kontermann’s leading knowledge in biotherapeutics. The collaboration aims to develop a new tool that will reduce costs of drug development by increasing the speed and success rate of pre-clinical studies.
Quality Control and Purification of New Biological Pharmaceuticals
Participants - Astra Zeneca AB, Attana AB, Akzo Nobel Pulp and Performance Chemicals AB and Karlstad University and three more partners.
Thursday November 30th 2017 the project BIO-QC "Quality Control and Purification of New Biological Pharmaceuticals" was initiated. Biological pharmaceuticals are proteins or similar molecules, which mimics molecules in the body and are injected in the body to stimulate the immune system. To provide criteria’s for quality control of biological pharmaceuticals.
The project has a budget of approximately €2 million and includes seven different parties, Attana AB, AstraZeneca, Akzo Nobel Pulp and Performance Chemicals AB and Ridgeview Instruments AB and Karlstad University, Linné University and Örebro University.
NanoCarb: Development of glycosylated nanoparticles with enhanced therapeutic actions
Participants - Royal College of Surgeons in Ireland, University of Warwick, Università degli Studi di Milano, CIC biomaGUNE, Vlaamse Instelling voor Technologisch Onderzoek, Ludger Ltd, Midatech Pharma, Mario Negri Institute for Pharmacological Research.
The overarching aim of the NanoCarb ETN project is to develop glycosylated nanoparticles with enhanced therapeutic actions for healthcare applications. 15 Early Stage Researchers (ESRs) recruited for the NanoCarb project will work on their individual ESR projects designed to provide appropriate research goals for PhD students. Each ESR will be exposed to a well-balanced and optimal experience in academia, industry and research centre in order to increase their research experience and scientific maturity.
CellSenseGels: Development of sensitive and robust cell-based biosensor assay platforms using peptide gel matrices
Participants - University Stuttgart, Biogelx Ltd, Attana AB.
The project will develop a robust sensitive platform for measurements of molecular kinetics, using peptide hydrogel technology as a 3D matrix. The gels will offer a tissue-mimicking environment, ensuring increased biological relevance and greater data quality. Furthermore, this sensor will improve the range and data quality of biosensor assays through increased signal strength and reduced background noise. Product will be cell-type optimized kits incorporating customised gel-matrices.
Development of CD34/CD3 bispecific antibodies for treatment of leukemia and preconditioning before allogeneic hematopoietic stem cell transplantation
Participants - Karolinska Universitetsjukhuset, Kungliga Tekniska Högskolan, Attana AB.
The aim of the project Specific aims of the project to design a range of bispecific antibodies towards CD34 (stem cells and leukemic cells) and CD3 (T cells) and to identify and select lead candidates by evaluating binding properties towards cell-surface bound antigen by Attanas' cell based assays.
NanoClassifier: QCM for rapid label-free Bionano interface evaluation and screening of effectiveness of nano-targeting strategies for therapeutics.
Participants - University College Dublin, Attana AB.
Nanomedicine and Nanosafety rely on the same fundamental interactions between the nanoparticle interface and the biological milieu surrounding it, and it is this “corona” of proteins and other biomolecules that form at the bionanointerface that determines the fate and behaviour of nanomaterials. Understanding, classifying and predicting nanoparticle coronas from their physicochemical properties offers a novel approach to screening for toxicity at early stages of product development and for regulatory purposes.
• Kinetic & Affinity Characterization – Polyclonal Antibodies
The primary goal of antibody production is to obtain high titer, high affinity antiserum for use in experimentation, diagnostic tests or therapy. Detection and monitoring of the purification of these polyclonal antibodies can be time consuming and troublesome. This Application Example demonstrates how the Attana C-Fast system can be used to rapidly characterize polyclonal antibodies raised against peptides and protein antigens. Polyclonal antibodies are by nature a mixture of antibodies, with their own respective kinetic characteristics and most probably also with differences in antigen epitope specificities. Due to this heterogeneity, the rate constants derived and the calculated affinity should be regarded as a mean of the different subpopulations.
• Crude Samples Analysis; Screening and Characterization of Hybridoma Supernatants
Purification, and sometimes labelling of antibodies before characterization of the antibody-antigen interactions can be very time consuming and associated with issues such as optimization and yield. The Attana system together with the Attana IgG capture kits can reduce these problems. Here we demonstrate an anti-mouse IgG surface with the ability to capture antibodies from crude materials, followed by a detailed study of the kinetics for the interactions between the antibody and its antigen.